VEGFA and hepatocellular carcinoma: Similar combinations using ICIs plus anti-VEGF/R signaling inhibitors have either been tested in phase I/II trials or under active phase III trials in HCC (Sangro et al., 2021; Finn et al., 2020c; Xu et al., 2021; Mei et al., 2021; Yau et al., 2020; Ren et al., 2021).